Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJTM
Special Issues
Trends of Translational Medicine for Oncology
share announcement

Trends of Translational Medicine for Oncology

A special issue of International Journal of Translational Medicine (ISSN 2673-8937).

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 23806

Special Issue Editor

Dr. Nuno Vale

E-Mail Website
Guest Editor
Department of Community Medicine, Health Information and Decision, Faculty of Medicine, University of Porto, Rua Dr. Plácido da Costa, 4200-450 Porto, Portugal
Interests: in silico pharmacology; PBPK; drug metabolism; drug combination; drug delivery; peptides; ADME; DMPK; pharmacokinetic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Translational research is crucial in informing clinical practice and trials. Bringing researchers and clinicians together and combining clinical information with basic research findings is the way to move the field forward, find the best solutions, and beat cancer. This Special Issue is actively conducting translational medicine research to further the understanding of cancer biology and to identify which patient populations may be more likely to benefit from treatments. Our goal is to develop new diagnostic procedures and more targeted treatment approaches by investigating the molecular and functional properties of different cancers. In addition, this Special Issue will evaluate potential diagnostic tools to help identify in patients biomarkers that require less invasive methods.

In the area of preclinical translation, there are numerous application-oriented lab projects focused on the pathogenesis of different cancers in order to identify new diagnostic options and points of attack for targeted treatments. In the area of clinical translation, the focus includes the development and systematic use of tools for comprehensive molecular, cellular, and functional characterization of individual tumors.

This Special Issue will include (but is not limited to) papers on:

  • biomarkers and pharmacodiagnostics;
  • imaging and technologies;
  • radiation oncology;
  • bioinformatics and integrated sciences;
  • clinical pharmacology and pharmacometrics.

Prof. Dr. Nuno Vale
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Translational Medicine is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacogenomic
  • individualized therapy
  • PBPK studies
  • tumor microenvironment
  • immuno-oncology
  • translational oncology
  • drug repurposing in oncology
  • process modeling
  • clinical trials
  • molecular and functional properties of cancers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (7 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

11 pages, 2088 KiB  
Article
Assessment of Gamma Knife Stereotactic Radiosurgery as an Adjuvant Therapy in First-Line Management of Newly Diagnosed Glioblastoma: Insights from Ten Years at a Neuroscience Center
by Jose E. Valerio, Aizik Wolf, Xiaodong Wu, Noe Santiago Rea, Maria Fernandez Gomez, Matteo Borro and Andres M. Alvarez-Pinzon
Int. J. Transl. Med. 2024, 4(2), 298-308; https://doi.org/10.3390/ijtm4020019 - 27 May 2024
Viewed by 1569
Abstract
Gamma knife radiosurgery (GKRS), a form of stereotactic radiosurgery (SRS), has gained importance in treating glioblastoma alongside conventional chemotherapy. This study aims to assess the efficacy of combining GKRS with surgery and chemotherapy to enhance treatment outcomes for glioblastoma patients. This prospective clinical [...] Read more.
Gamma knife radiosurgery (GKRS), a form of stereotactic radiosurgery (SRS), has gained importance in treating glioblastoma alongside conventional chemotherapy. This study aims to assess the efficacy of combining GKRS with surgery and chemotherapy to enhance treatment outcomes for glioblastoma patients. This prospective clinical study, adhering to STROBE guidelines, assessed 121 glioblastoma patients from June 2008 to December 2022. All patients who had not undergone prior radiotherapy underwent open surgical tumor resection, GKRS, and adjuvant chemotherapy. In the analyzed cohort, the median survival post-diagnosis was 21.2 months (95% CI: 11.4–26.7) and the median progression-free survival was 13.6 months (95% CI: 12.5–28.3). The median time to first recurrence post-treatment was 14.5 months (range: 4–33 months). The median prescribed dose for GKRS was 12 Gy (range: 10–17 Gy), with a median target volume of 6.0 cm3 (range: 1.6–68 cm3). Post GKRS, 92 patients experienced local recurrence, 21 experienced distant recurrence, and 87 received additional treatment, indicating diverse responses and treatment engagement. This study evaluates the use of GKRS for glioblastomas, emphasizing its efficacy and complications in a single-center trial. It suggests integrating GKRS into initial treatment and for recurrences, highlighting the comparable survival rates but underscoring the need for further research. Full article
(This article belongs to the Special Issue Trends of Translational Medicine for Oncology)
►▼ Show Figures

Figure 1

15 pages, 908 KiB  
Article
Efficacy and Safety of Brazilian Green Propolis in Biochemically Recurrent Prostate Cancer after Radical Prostatectomy: A Single-Arm Phase II Study
by Takayuki Goto, Hiroko Kimura, Takayuki Yoshino, Atsuro Sawada, Shusuke Akamatsu, Takashi Kobayashi, Toshinari Yamasaki, Shigemi Tazawa, Masakazu Fujimoto, Yu Hidaka, Ryuji Uozumi, Satoshi Morita, Osamu Ogawa and Takahiro Inoue
Int. J. Transl. Med. 2022, 2(4), 618-632; https://doi.org/10.3390/ijtm2040047 - 17 Dec 2022
Viewed by 2504
Abstract
Background: Radiation or hormonal therapy is considered for prostate cancer patients with biochemical recurrence (BCR) after radical prostatectomy (RP). However, these therapies have their own complications. To delay the start of these therapies, we investigated the efficacy and safety of Brazilian green propolis [...] Read more.
Background: Radiation or hormonal therapy is considered for prostate cancer patients with biochemical recurrence (BCR) after radical prostatectomy (RP). However, these therapies have their own complications. To delay the start of these therapies, we investigated the efficacy and safety of Brazilian green propolis for the treatment for BCR after RP. Materials and Methods: This single-center, single-arm open trial included 22 patients who experienced BCR after RP between 2016 and 2019. The patients received nine softgels of Brazilian green propolis (containing 40 mg propolis per capsule) daily for 6 months. The primary outcome was the prostate-specific antigen (PSA) response rate. The secondary outcomes included progression-free time, PSA slope (1/PSA doubling time) response rate, quality of life, and safety profile. Results: The PSA response rate was 0%. The mean PSA slopes before and after baseline were 0.12 month−1 and 0.08 month−1, respectively. Fifteen patients (68%) showed a decreased PSA slope after treatment. There were no negative effects on quality of life or serious adverse events leading to treatment discontinuation. Conclusion: There was no significant anticancer response in patients who received Brazilian green propolis. However, the PSA slope was decreased after propolis administration. Further, Brazilian green propolis may be safely consumed by patients. Full article
(This article belongs to the Special Issue Trends of Translational Medicine for Oncology)
►▼ Show Figures

Figure 1

12 pages, 2247 KiB  
Article
Celosia trigyna Linn (Cucurbitaceae) Annihilate Human Breast, Colon, and Lung Cancer Cells: Combination of Cheap Template for Anticancer Screening
by Adedokun Oluwasegun, Epole Ntungwe, Ayinde Bunyamin, Lucilia Saraiva, Salvatore Princiotto and Patrícia Rijo
Int. J. Transl. Med. 2022, 2(4), 574-585; https://doi.org/10.3390/ijtm2040043 - 30 Nov 2022
Viewed by 1864
Abstract
Celosia trigyna is a well-known vegetable used in the preparation of many indigenous soups in Southwestern Nigeria. The aim of this study was to evaluate the anticancer property of C. trigyna of crude and solvent fractions using antioxidant, cytotoxic bench-top bioassays, and cancer [...] Read more.
Celosia trigyna is a well-known vegetable used in the preparation of many indigenous soups in Southwestern Nigeria. The aim of this study was to evaluate the anticancer property of C. trigyna of crude and solvent fractions using antioxidant, cytotoxic bench-top bioassays, and cancer cell line experiments. Cytotoxicity was carried out using Raniceps ranninus, Saccharomyces cerevisiae, and Sorghum bicolor models, as well as cytotoxicity studies against human breast (MCF), colon (HCT116), and lung (H460) cancer cell lines; radical scavenging potential against DPPH was likewise performed. A concentration of nondependent cytotoxicity against S. cerevisiae was observed in CTA, with the lowest inhibition of organism growth at 31.2 µg/mL (26.40 ± 1.92%) and highest activity at 250 µg/mL (56.00 ± 2.12%). Concentration-dependent inhibition was observed in CTA with 84.80 ± 1.97% at 250 µg/mL, which is significantly different from values observed in DMSO (negative control) at 33.84 ± 1.03% at p < 0.01. Moreover, 100% motility of R. ranninus (tadpoles) was recorded for all concentrations (20–40 µg/mL) in CT and CTA, with significantly different p < 0.05 from values obtained for the vehicle (distilled water). Concentration-dependent DPPH radical scavenging potential was likewise noted both in CT and CTA at 20–100 µg/mL. The lowest inhibition was observed at 20 µg/mL (41.35% and 32.31%), while the highest was noted at 100 µg/mL (63.26% and 41.73%) for CT and CTA, respectively. CT showed cytotoxic effects against all cancer cell lines examined, with CTA exhibiting improved activity compared to CT against human lung (H460), breast (MCF-7), and colon (HCT116) cancer cell lines, with IC50 51.69 ± 5.13, 39.16 ± 9.21, and 38.52 ± 7.65, respectively. Findings from this research experimentally justify the ethnomedicinal claim of usage of C. trigyna in the treatment of cancer in southwestern Nigeria. Full article
(This article belongs to the Special Issue Trends of Translational Medicine for Oncology)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

29 pages, 5220 KiB  
Review
A Concise Review of Prodigious Salinomycin and Its Derivatives Effective in Treatment of Breast Cancer: (2012–2022)
by Viren Soni, Akhil Nagar, Ruchita Bardiya, Jacob Mara, Lukas Von Suskil, Sabrina Rose and Chetankumar Sonawane
Int. J. Transl. Med. 2023, 3(2), 217-245; https://doi.org/10.3390/ijtm3020016 - 5 May 2023
Viewed by 3491
Abstract
Cancer stem cells (CSCs) are the cells in a primary tumor that have the opportunity to self-renew as well as differentiate into certain cell types, thus forming a mixed tumor. CSCs have been shown to be involved in every aspect of cancer development, [...] Read more.
Cancer stem cells (CSCs) are the cells in a primary tumor that have the opportunity to self-renew as well as differentiate into certain cell types, thus forming a mixed tumor. CSCs have been shown to be involved in every aspect of cancer development, including tumor initiation, proliferation, and metastatic activity; they are also involved in chemotherapeutic drug resistance and the recurrence of certain cancers. Based on these capabilities, CSCs have been explored as the next target for the treatment and management of cancer. Salinomycin (SAL), a polyether ionophore antibiotic being used in the poultry industry, was identified as a powerful anti-cancer compound that possesses broad-spectrum activities, especially against CSCs. Here we point out the noteworthy work reported on SAL’s mechanism of action, anticancer activities, toxicity, and clinic applications. In addition, SAL derivatives synthesized by different research groups and their biological activity will also be highlighted. Full article
(This article belongs to the Special Issue Trends of Translational Medicine for Oncology)
►▼ Show Figures

Figure 1

19 pages, 1079 KiB  
Review
Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches
by Niloofar Khoshdel Rad, Maryam Vahidyeganeh, Mahsa Mohammadi, Anastasia Shpichka, Peter Timashev, Nikoo Hossein-Khannazer and Massoud Vosough
Int. J. Transl. Med. 2022, 2(4), 555-573; https://doi.org/10.3390/ijtm2040042 - 23 Nov 2022
Cited by 2 | Viewed by 4291
Abstract
Non-clear cell renal cell carcinomas (nccRCC) are a diverse group of kidney cancers with histopathologically and genetically heterogeneous features. About 25% of renal cell carcinomas (RCCs) are nccRCC types. The management and treatment of nccRCCs are rather limited, and the data are often [...] Read more.
Non-clear cell renal cell carcinomas (nccRCC) are a diverse group of kidney cancers with histopathologically and genetically heterogeneous features. About 25% of renal cell carcinomas (RCCs) are nccRCC types. The management and treatment of nccRCCs are rather limited, and the data are often estimated from studies in the more common clear cell renal cell carcinoma (ccRCC). Each subtype has its own distinctive biological and therapeutic profile. Our knowledge of the underlying biological features of nccRCC has directed and continues to shape the use of novel therapy targeting the main signaling pathways and leading to improved overall survival (OS) of the patients. This review discusses the characteristic molecular features of the major types of nccRCC and current cell-based and animal models for studying them. In the following, we highlighted major signaling pathways and therapeutic approaches for nccRCC patients. Full article
(This article belongs to the Special Issue Trends of Translational Medicine for Oncology)
►▼ Show Figures

Figure 1

29 pages, 2288 KiB  
Review
Osteopontin in Cancer: Mechanisms and Therapeutic Targets
by Yoshinobu Kariya and Yukiko Kariya
Int. J. Transl. Med. 2022, 2(3), 419-447; https://doi.org/10.3390/ijtm2030033 - 19 Aug 2022
Cited by 4 | Viewed by 6810
Abstract
Despite significant advances in the understanding of cancer biology, cancer is still a leading cause of death worldwide. Expression of the tumor microenvironment component, osteopontin, in tumor tissues, plasma, and serum, has been shown to be associated with a poor prognosis and survival [...] Read more.
Despite significant advances in the understanding of cancer biology, cancer is still a leading cause of death worldwide. Expression of the tumor microenvironment component, osteopontin, in tumor tissues, plasma, and serum, has been shown to be associated with a poor prognosis and survival rate in various human cancers. Recent studies suggest that osteopontin drives tumor development and aggressiveness using various strategies. In this review, we first provide an overview of how osteopontin promotes tumor progression, such as tumor growth, invasion, angiogenesis, and immune modulation, as well as metastasis and chemoresistance. Next, we address how the functional activities of osteopontin are modulated by the interaction with integrins and CD44 receptors, but also by the post-translational modification, such as proteolytic processing by several proteases, phosphorylation, and glycosylation. Then, we review how osteopontin activates tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), and functions as an immunosuppressor by regulating immune surveillance and immune checkpoint in the tumor microenvironment. Finally, we discuss the potential applications of osteopontin as a biomarker and as a therapeutic target. Full article
(This article belongs to the Special Issue Trends of Translational Medicine for Oncology)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

6 pages, 1138 KiB  
Case Report
Primary Mucosa-Associated Lymphoid Tissue Lymphoma of the Parotid Gland in 32-Year-Old Male, a Case Report
by Bianca M. Glass, Mira Al Jaberi, John H. Irlam and Samir M. Dalia
Int. J. Transl. Med. 2023, 3(4), 426-431; https://doi.org/10.3390/ijtm3040030 - 11 Oct 2023
Viewed by 1709
Abstract
Primary lymphomas of the salivary gland are rare. The most common subtype is MALT lymphoma. MALT lymphoma has an indolent clinical course, and patients often present with a prolonged history. Evaluations of parotid masses begin initially with radiological imaging, but pathological and histological [...] Read more.
Primary lymphomas of the salivary gland are rare. The most common subtype is MALT lymphoma. MALT lymphoma has an indolent clinical course, and patients often present with a prolonged history. Evaluations of parotid masses begin initially with radiological imaging, but pathological and histological examination remains the mainstay of definitive diagnosis. This case describes a primary non-Hodgkin’s lymphoma of the parotid gland in a healthy 32-year-old male. This case report will evaluate the prevalence of primary MALT lymphoma and discuss the possible presentation. Full article
(This article belongs to the Special Issue Trends of Translational Medicine for Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Back to TopTop